California, USA – July 30, 2026–INNOVITA concluded a successful participation at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Meeting & Clinical Lab Expo, held at the Anaheim Convention Center in California, USA. Under the theme "One Sample. Multiple Answers.", the company presented its comprehensive diagnostic portfolio alongside its strategic reagent and raw material platforms, demonstrating the technological capabilities that enable high-quality diagnostic solutions from the very foundation.
Comprehensive Technologies Supporting Global Diagnostic Needs
Recognizing the diverse epidemiological characteristics across different regions, INNOVITA showcased six major diagnostic portfolios covering Respiratory Diseases, Gastrointestinal Diseases, Tropical Diseases, Hepatitis & Sexually Transmitted Infections, TORCH, and Animal Health.
Visitors showed strong interest in INNOVITA's multiplex testing approach, which enables multiple diagnostic insights from a single patient sample. In particular, solutions designed for tropical and emerging markets attracted significant attention for their ability to shorten diagnostic turnaround, improve clinical decision-making, and better address local healthcare challenges.
Strengthening Innovation Through Vertical Integration
Unlike conventional IVD manufacturers focused primarily on assay assembly, INNOVITA highlighted its Pathogen Culture Platform and Genetic Recombinant Protein Engineering Platform at an international exhibition for the first time.
These proprietary technology platforms demonstrate the company's capability to develop and manufacture key biological raw materials in-house, providing greater control over product quality, consistency, and innovation. This vertically integrated approach not only strengthens INNOVITA's technological foundation but also enhances supply chain reliability for partners worldwide.
Meaningful Conversations Driving Localized Solutions
Throughout the exhibition, INNOVITA welcomed laboratory professionals, clinicians, distributors, and industry partners from across the globe. Productive discussions focused on the unique diagnostic challenges faced by different regions and healthcare systems.
Supported by its integrated raw material platforms, INNOVITA is able to respond rapidly to evolving pathogen trends, optimize assay design and manufacturing processes, and develop localized diagnostic solutions aligned with regional clinical practices and regulatory requirements. This customer-focused approach received positive recognition from visitors seeking flexible and market-specific diagnostic partnerships.
Advancing Diagnostics for a Global Future
The successful conclusion of ADLM 2026 marks another important milestone in INNOVITA's global expansion.
As the company continues to strengthen its international presence, it remains committed to advancing diagnostic technologies through continuous innovation in biological raw materials, assay development, and integrated technology platforms. Looking ahead, INNOVITA will continue to collaborate with partners worldwide to deliver reliable, high-quality diagnostic solutions that improve clinical efficiency and expand access to healthcare across diverse markets.
Diagnostics, Wherever Care is Needed.